Join us to learn how Carmell Corp (Nasdaq: CTCX) is bringing the biggest technological revolution in regenerative skin and haircare to the fast-growing ~$500 billion aesthetics industry.

Carmell’s Secretome^TM technology delivers 1000+ growth factors, proteins and peptides extracted from allogeneic human platelets in a 12-month shelf-stable and biologically active formulation. Carmell’s technology was previously being developed as a BLA and has Phase 2 Human clinical data supporting safety and efficacy. In comparison, other aesthetic products feature 1-2 synthetic proteins with sparse evidence of clinical efficacy.

Besides the Carmell Secretome^TM, the Company has also developed a novel nanoformulation that is ~1000x smaller than red blood cells enabling superior permeability of its ingredients into the stratum corneum.

Carmell aims to launch a limited-edition product this month followed by 9 other skincare products over the summer 2024. They are also developing a topical haircare product.

The event will feature Rajiv Shukla, Chairman & CEO of Carmell, joined by key opinion leaders (KOLs) Gilles Spenlehauer, PhD (former Worldwide head of research for L’Oreal, the world’s #1 cosmetics company) and Leonard Miller MD, FACS, FRCS (Clinical Instructor at Harvard Medical School, Founder of Boston Center for Plastic Surgery). Both KOLs are also advisors on Carmell’s Scientific Advisory Board.

Discussion Agenda

• Market Opportunity
• Product Differentiation
• Upcoming Launch Objectives and Timeline
• The Next Product Candidates in Carmell’s Portfolio

A live question and answer session will follow the formal presentations.